Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050271 · ClinicalTrials.gov registry record · NA
Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT00050271: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00050271 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050271, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and tolerable in HIV patients who have taken certain anti-HIV drugs.
Interventions
- DRUG Acetyl-L-carnitine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Est. Completion | 2007-01 |
| Phase | NA |
What the finished NCT00050271 record still lists
NCT00050271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Acetyl-L-carnitine is the first listed.
NCT00050271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050271 about?
NCT00050271 is a clinical study titled "Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy". The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and tolerable in HIV pat...
What is the current status of trial NCT00050271?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00050271?
The interventions under investigation include: Acetyl-L-carnitine (DRUG).
Who is sponsoring clinical trial NCT00050271?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00050271's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery